The emergence of human induced pluripotent stem cells (hiPSCs) and efficient
differentiation of hiPSC-derived cardiomyocytes (hiPSC-CMs) induced from diseased …

In recent years, the incidence of breast cancer has been increasing on an annual basis.
Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human …

The immature physiology of cardiomyocytes derived from human induced pluripotent stem
cells (hiPSCs) limits their utility for drug screening and disease modelling. Here we show …

Human pluripotent stem cell (hPSC) technology has offered nearly infinite opportunities to
model all kinds of human diseases in vitro. Cardiomyocytes derived from hPSCs have …

The development of new cardioprotective approaches using in vivo models of ischemic
heart disease remains challenging as differences in cardiac physiology, phenotype, and …

Background Intravenous administration of mesenchymal stromal cells (MSCs) has an
acknowledged competence of cardiac repair, despite a lack of systematic description of the …

Cancer is one of the leading causes of morbidity and mortality worldwide. Significant
improvements in the modern era of anticancer therapeutic strategies have increased the …

In vitro modelling the complex (patho‐) physiological conditions of the heart is a major
challenge in cardiovascular research. In recent years, methods based on three‐dimensional …

Many anticancer therapies (CTx) have cardiotoxic side effects that limit their therapeutic
potential and cause long-term cardiovascular complications in cancer survivors. This has …

Manifestations of cardiovascular diseases (CVDs) in a patient or a population differ based
on inherent biological makeup, lifestyle, and exposure to environmental risk factors. These …